Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide predictor study for obesity across the binge eating spectrum
2026-526016-36-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, sponsored by UZ Leuven. Primary endpoints: Change in BMI and Change in Binge Eating Scale score. Planned start Aug 2026; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2026-526016-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526016-36-00.